Skip to main navigation Skip to search Skip to main content

Targeting the tumor microenvironment by immunotherapy: Part 2

  • Judith Leibovici*
  • , Orit Itzhaki
  • , Monica Huszar
  • , Judith Sinai
  • *Corresponding author for this work
  • Tel Aviv University

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations

Abstract

Cancer therapy was traditionally centered on the neoplastic cells. This included mainly surgery, radiation, and chemotherapy, in some cases hormone therapy and to a lesser extent immunotherapy - all traditionally targeted to the highly proliferating mutated tumor cells. In view of our present understanding of the powerfull influence of the tumor microenvironment (TME) on cancer behavior and response - and lack of response - to treatment, this previously ignored constituent of cancer now has to be considered as an important, even indispensable target for therapy. The TME may be targeted both to its immune and to its nonimmune components. The various immune evasion elements of the TME should be targeted as well.

Original languageEnglish
Pages (from-to)1385-1408
Number of pages24
JournalImmunotherapy
Volume3
Issue number11
DOIs
StatePublished - Nov 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • cancer immunotherapy
  • growth promoting targets
  • immune evasion targets
  • immune targets
  • nonimmune targets
  • tumor microenvironment

Fingerprint

Dive into the research topics of 'Targeting the tumor microenvironment by immunotherapy: Part 2'. Together they form a unique fingerprint.

Cite this